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similar for patients with NIDDM and non-diabetics. Clinically driven
TVR was 5.97% for diabetics and 3.38% for non-diabetic patients.
Deﬁnite or probable ST occurred in 0.9% for diabetic and non-diabetic
patients, and in 1.0% of patients with IDDM.
CONCLUSIONS In this registry, diabetic patients receiving a Biolimus
A9–eluting DES had a signiﬁcantly higher rate of MACE than non-
diabetics, but similar and low rates of ARC deﬁnite or probable stent
thrombosis at 3 y of follow up.
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BACKGROUND The e-Biomatrix registry is a prospective, multi-
center, observational registry investigating the long-term clinical
events after treating a “real world, all-comers” patient population
with either BioMatrix or BioMatrix Flex stents. This BA9-
eluting stent (BES) has an abluminal biodegradable polymer coating,
which disappears within 9 months, and is intended to prevent the
late events that may be associated with the existence of durable
polymer. This work presents the inﬂuence of comorbidities on out-
comes in this setting. We present the ﬁnal result of our study on the
impact of comorbidities (using the Charlson’s comorbidity index) on
clinical outcomes.
METHODS We used the Charlson comorbidity index (CCI), a scoring
system involving weighting factors on the basis of disease severity,
including cardiovascular diseases, diabetes, renal failure, chronic
infections and malignant tumors. Among 5472 patients in this reg-
istry, 2953 (54%) had at least one comorbidity, of which the most
common comorbidities were prior myocardial infarction (24.9% of
the population), diabetes mellitus (24.1%), peripheral vascular dis-
ease (6.8%), congestive heart failure (5.2%), chronic obstructive
pulmonary disease (5.2%), cerebral vascular disease (5.7%) and renal
failure (2.7%). Four patient subgroups with Charlson comorbidity
indices equal to 0, 1, 2, and 3 are deﬁned as follows: CCI-0 (no
comorbidity; n¼ 2517), CCI-1 (CCI¼1; n¼1709), CCI-2 (CCI¼2; n¼694),
CCI3 (n¼550). With increasing CCI, patients were older, had higher
rates of hypertension, hypercholesterolemia, and obesity, but were
less often current smokers. They had undergone increasingly often a
prior PCI or CABG and had more often decreased LV ejection frac-
tion. LVEF <40%: CCI-0: 4.78%, CCI-1: 6.5%, CCI-2: 14.19%, CCI3:
28.1%; p<0.01. Compared to the other groups, patients with CCI3
underwent PCI less often for STEMI (CCI-0: 41.7%, CCI-1: 30.3%,
CCI-2: 25.7%, CCI3: 13.8%).
RESULTS At 1 year, the comparison of the subgroups by the Kaplan-
Meier curves suggested a direct correlation between CCI and MACE,
but not between CCI and bleeding or stent thrombosis. However, in a
multivariate analysis CCI was shown to be no longer an independent
predictor of MACE. The ﬁnal 36-months data including the primary
endpoint (MACE), Mortality, MI, stent thrombosis and bleeding, is in
the process of being analyzed and will be reported at the time of
presentation. Furthermore, the results of the multivariate analysis
will be reported to identify the independent predictors of 36-month
mortality, MACE, and major bleeding.
CONCLUSIONS This large international study demonstrates the
impact of comorbidities on long-term safety and efﬁcacy outcomes in
patients undergoing PCI. The complete ﬁnal 3-year follow-up analysis
will be available at the time of the meeting.
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BACKGROUND A post marketing clinical follow-up study was
conducted evaluating the continued safety and effectiveness of the
CE-mark approved DESyne Novolimus Eluting Coronary Stent
System (NECSS) (Elixir Medical, Sunnyvale, CA), a Co-Cr stent with
a durable biocompatible polymer and Novolimus, a macrocyclic
lactone mTOR inhibitor. The drug dose is 5 mg per mm of stent
length.
METHODS A total of 57 patients were enrolled into the EXCELLA Post-
marketing Clinical Follow-up (PMCF) study. All were treated with the
DESyne NECSS for de novo lesions in native coronary arteries with a
reference vessel diameter between 2.5 and 4.0mm treatable with
stents between 14 and 38 mm in length. Patient data were analyzed
for the clinical endpoints of major adverse cardiac events (MACE)
deﬁned as: cardiac death, target vessel MI, clinically-indicated target
lesion revascularization (TLR); target vessel revascularization and
stent thrombosis at 1, 9, 12 and 24 months. The study was approved
the local Ethics Committees and all patients provided informed
consent.
RESULTS Patients were enrolled between February 2014 and May
2014, in Germany, Jordan and Spain. After the index procedure, pa-
tients were contacted at 1, 9 and 12 months either via an ofﬁce visit or
telephonically. The mean age of patients was 62 years; 38.6% were
diabetics and 72% presented with hypercholesterolemia and 72% with
hypertension and 12.3% had unstable angina. Baseline lesion charac-
teristics revealed 51% type C lesion with a mean reference vessel
diameter of 2.84  0.45mm and lesion length of 17.27  8.73mm.
Clinically, the DESyne NECSS demonstrates excellent safety with no
clinical events reported through 30 days and continued low MACE
rates through 12 months; with the full demographic, lesion and clin-
ical data through 12 months to be presented.
CONCLUSIONS The DESyne NECSS continues to demonstrate excel-
lent clinical safety similar to the clinical safety results seen in the
pivotal EXCELLA II Randomized Study. Demographic and clinical re-
sults through 12 months will be presented.
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BACKGROUND The Resolute IntegrityTM zotarolimus-eluting stent
(ZES; Medtronic, Inc.) is designed with a single continuous wire
formed into a repeating sinusoidal pattern (as compared with discrete
rings with the previous Resolute ZES) with the goal to enhance
deliverability. The objective of RESOLUTE INTEGRITY US Zotar-
olimus-Eluting Coronary Stent System Clinical Study is to investigate
outcomes with Resolute Integrity ZES.
METHODS The RESOLUTE INTEGRITY US study is a multi-center,
single-arm, open label study in the United States that enrolled pa-
tients with de novo lesions with length 30 mm and vessel diameter
of 2.25 to 4.2 mm. Clinical outcomes have not been previously re-
ported. Patients will have been followed for two years by the time of
TCT 2015.
RESULTS The RESOLUTE INTEGRITY US study enrolled 230 patients
(251 lesions); 42% had diabetes mellitus, including 17% with insulin-
dependent diabetes mellitus, 24% prior myocardial infarction, 83% of
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year, target lesion failure was 5.0% (11/220), and comprised of target
lesion revascularization 2.3% (5/220), cardiac death 1.4% (3/220), and
target vessel myocardial infarction 2.3% (5/220). ARC deﬁnite/prob-
able stent thrombosis was 0.9% (2/220) at one year. Outcomes at 12
months were also similar in patients with and without DM (Figure).
CONCLUSIONS The RESOLUTE INTEGRITY US study included a large
number of diabetic patients and patients with complex anatomy. Use
of Resolute Integrity ZES was associated with excellent device success
and clinical outcomes, including in patients with diabetes mellitus, at
one year. Two-year outcomes will be available at the time of TCT 2015.
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BACKGROUND The beneﬁts of new-generation drug eluting stents
(DES) in women with multiple atherothrombotic risk factors are
unclear.
METHODS The purpose of the current study was to investigate: (i) the
impact of high atherothrombotic (AT) risk on clinical outcomes in
women undergoing percutaneous coronary intervention (PCI) with
drug-eluting stent (DES) and (ii) the effect of new-generation DES,
compared with early-generation, in women with versus without high
AT risk. We pooled patient-level data for women enrolled in 26 ran-
domized trials. Study population was categorized based on the pres-
ence or absence of high AT risk, which was deﬁned as having history
of diabetes mellitus, prior percutaneous or surgical revascularization,
or prior myocardial infarction (MI). The primary endpoint was majoradverse cardiovascular events (MACE) at 3 years, deﬁned as the
composite of death, MI, target lesion revascularization or stent
thrombosis. Women who received a bare-metal stent were excluded
from this analysis.
RESULTS Out of 10,449 women included in the pooled database, 5333
(51%) had high AT risk. A signiﬁcantly higher crude rates of 3-year
MACE was observed in women with versus without high AT risk (15.8
% vs. 10.6%; p < 0.0001). Following multivariable adjustment, high
AT risk was independently associated with higher 3-year risk of MACE
(HR: 1.50; 95% CI: 1.23 – 1.83; p <0.0001) and all-cause mortality (HR:
1.69; 95% CI: 1.18 – 2.38; p ¼ 0.003). Compared with early-generation
DES, in women at high AT risk, the use of new-generation DES was
associated with signiﬁcantly lower risk of MACE at 3 years (HR:0.79;
95% CI:0.63-0.99; p ¼ 0.04). New-generation DES had no signiﬁcant
effect on all-cause mortality in high AT risk women (HR: 0.69; 95% CI:
0.47 – 1.02; p ¼ 0.06).The effect of new-generation DES was uniform
between high and non-high AT risk women, without evidence of
interaction.
CONCLUSIONS Use of new-generation DES in women with multiple
risk factors for atherothrombosis is associated with a lower risk for
long-term adverse ischemic events compared with early-generation
DES.
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BACKGROUND Predictive factors of atherothrombotic events in
women after implantation of drug eluting stents (DES) are unclear.
Prior studies of this subject were conducted on predominantly male
patient populations.
METHODS The objective of the current study was to investigate the
predictive factors of atherothrombotic events in female patients with
DES relative to the time when these events occurred. We pooled pa-
tient-level data from 26 randomized controlled trials of DES. The
primary endpoint was the risk of intracoronary thrombotic event (ITE)
at 3 years, deﬁned as the composite of stent thrombosis or myocardial
infarction. The timing of ITEs was subdivided into early (occurring 
30 days after DES placement), late (31 days to 1 year), and very late (>1
year). Predictive factors of ITEs were analyzed via multivariable Cox
regression models at each time point. Women who received a bare
metal stent were excluded from this analysis.
RESULTS Out of 10,449 women in the pooled dataset, 345 (3.0%) had
an early ITE, 113 (1.0%) had a late ITE, and 133 (1.0%) had a very late
ITE. Per the multivariable analysis, the independent predictors for
cumulative ITE at 3 years were patient age (per year increase; HR: 1.01;
95%CI: 1.00-1.02; p¼0.05), diabetes mellitus (HR: 1.39; 95% CI:1.12-
1.73; p¼0.003), arterial hypertension (HR: 1.41; 95% CI: 1.05-1.91;
p¼0.02), previous percutaneous coronary intervention (HR: 1.35; 95%
CI: 1.05-1.75; p¼0.02), use of ﬁrst-generation DES (HR: 1.30; 95% CI:
1.02-1.65; p¼0.03), multivessel disease (1.29; 95% CI: 0.99-1.67;
p ¼0.05), number of stents implanted (per additional stent implanted;
